US Patent

US9474752 — Method for treating a pulmonary hypertension condition

Method of Use · Assigned to Gilead Sciences Inc · Expires 2027-12-11 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for treating pulmonary arterial hypertension in a subject by administering a therapeutically effective amount of ambrisentan within 2 years of diagnosis.

USPTO Abstract

A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.

Drugs covered by this patent

Letairis (AMBRISENTAN) · Gilead Sciences

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1754`	—	Letairis
`U-1754`	—	Letairis

Patent Metadata

Patent number: US9474752
Jurisdiction: US
Classification: Method of Use
Expires: 2027-12-11
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.